Medicamen Biotech Ltd: Q2 FY27 Results Trend Check
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Results
Medicamen Biotech Ltd CMP Rs 320.5. Q1 FY27 revenue Rs 47.9 cr, net profit Rs 1.85 cr. Q2 FY26 base Rs 47.17 cr revenue, Rs 2.12 cr profit. PE 40.11.
Medicamen Biotech Q2 results season is approaching for the quarter ending September 2026, and this preview looks strictly at the company’s own reported numbers rather than any outside estimate. Track the latest Medicamen Biotech Ltd. share price on Univest before the Medicamen Biotech Q2 results preview below.
Medicamen Biotech Q2 Results Date: When to Expect the FY27 Announcement
No official Medicamen Biotech Q2 results date has been announced yet for the quarter ended September 30, 2026. Pharma companies, including Medicamen Biotech Ltd, typically announce September-quarter results in the October-November window, and the Medicamen Biotech Q2 results date for FY27 should be confirmed once the board meeting is intimated to the exchanges. Investors tracking the Medicamen Biotech Q2 results 2026 announcement should rely only on official filings for the confirmed date.
Open a Univest demat account to track Medicamen Biotech Ltd ahead of results season.
Medicamen Biotech Q2 Results Expectations: What the Numbers Suggest
Also read – Dabur India Q2 Results FY27 Preview
Medicamen Biotech Q2 results expectations for FY27 cannot be built on invented forecasts, but the company’s own five-quarter trend gives a factual base. Revenue moved from Rs 43.04 crore in Jun25 to Rs 47.9 crore in Jun26, with a one-off spike to Rs 60.65 crore in Mar26 that normalized the following quarter. Ahead of the Medicamen Biotech Q2 results for the Sep26 quarter, the metrics worth tracking are revenue continuity near the Rs 47-48 crore range, operating margin stability, and net profit consistency after the Mar26 one-off.
Previous Quarter: Q1 FY27 (Jun26) Performance
In the quarter immediately before the Medicamen Biotech Q2 results period, the company reported revenue of Rs 47.9 crore for Jun26, operating profit of Rs 4.33 crore, and an operating margin of 9.04%. Net profit for Q1 FY27 was Rs 1.85 crore. Per the company’s own screener data, the Mar26 sales and net profit spike normalized in Jun26, likely reflecting a seasonal or one-off order bump. These Q1 FY27 numbers form the immediate run-up to the Medicamen Biotech Q2 results for the Sep26 quarter.
Q2 FY26 (Sep25) Base Quarter: The Comparison Base for Q2 Results
The Sep25 quarter is the year-ago base against which the Medicamen Biotech Q2 results for FY27 will eventually be compared. In Sep25, revenue was Rs 47.17 crore, operating profit was Rs 5.16 crore, and operating margin was 10.94%, the highest margin reading in this five-quarter data set. Net profit that quarter was Rs 2.12 crore. Any year-on-year comparison in the upcoming Medicamen Biotech Q2 results will be measured against this Rs 47.17 crore revenue and Rs 2.12 crore profit figure.
Recent Trend: Jun25 Through Jun26
Looking at the full run of reported quarters ahead of the Medicamen Biotech Q2 results for FY27, revenue was Rs 43.04 crore (Jun25), Rs 47.17 crore (Sep25), Rs 46.91 crore (Dec25), Rs 60.65 crore (Mar26) and Rs 47.9 crore (Jun26). Operating margin drifted lower across the period, from 10.71% in Jun25 to 9.04% in Jun26, while net profit ranged between Rs 1.6 crore and Rs 4.45 crore, with the Mar26 figure of Rs 4.45 crore standing out as the peak before normalizing to Rs 1.85 crore in Jun26. This five-quarter history is the only verified base for the Medicamen Biotech Q2 results in FY27.
Key Factors to Watch Ahead of Medicamen Biotech Q2 Results
Based strictly on the reported trend, a few factors are worth tracking ahead of the Medicamen Biotech Q2 results for FY27. First, whether revenue holds near the Rs 47-48 crore range seen in Jun25, Sep25, Dec25 and Jun26, given the Mar26 figure was flagged in the company’s own data as a likely one-off. Second, operating margin direction, since it has gradually eased from 10.94% in Sep25 to 9.04% in Jun26. Third, whether net profit stays in the Rs 1.6-2.1 crore range typical of most quarters, rather than repeating the Mar26 spike. These are observations from the company’s own numbers, not forecasts for the Medicamen Biotech Q2 results 2026 cycle.
Valuation Ahead of Medicamen Biotech Q2 Results
Also read – Dalmia Bharat Q2 Results FY27 Preview
At a CMP of Rs 320.5, Medicamen Biotech Ltd trades at a trailing PE of 40.11 and a price-to-book (PB) ratio of 1.58, against a book value of Rs 203 per share. Return on equity (ROE) is 3.95%, and the debt-to-equity (DE) ratio is 0.17. The stock carries an EPS of Rs 7.99 and a dividend yield of 0.31%. Market capitalisation is around Rs 435 crore. These figures give context for the Medicamen Biotech Q2 results FY27 valuation conversation once the actual numbers are reported.
Want to follow live price action alongside the Medicamen Biotech Q2 results? Start with a free Univest demat account.
What to Watch in the Medicamen Biotech Q2 Results Preview
As this Medicamen Biotech Q2 results preview makes clear, the company’s own five-quarter trend is the most reliable reference point for the Sep26 quarter. Watch for the confirmed Medicamen Biotech Q2 results date once the board meeting notice is filed. Watch revenue relative to the Rs 47.9 crore reported in Jun26 and the Rs 47.17 crore reported in the Sep25 base quarter. Watch operating margin relative to the 9.04%-10.94% range, and watch whether net profit stays in its typical band after the Mar26 one-off.
Conclusion
The Medicamen Biotech Q2 results for FY27 have not yet been announced, and this preview has stuck to the company’s own reported Jun25 through Jun26 numbers rather than any invented forecast. Medicamen Biotech Ltd’s revenue, operating margin and net profit history give investors a factual base to track once the Sep26 quarter numbers are filed. The Medicamen Biotech Q2 results, once out, should be read alongside the company’s official exchange filings.
Stay prepared for results season: open your Univest demat account today.
Univest is a SEBI-registered Research Analyst (Registration No. INH000013776). This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Historical quarterly figures for Medicamen Biotech Ltd are based on company-reported data; commentary on the Sep 2026 (Q2 FY27) quarter is forward-looking framing only, since results for that quarter have not yet been announced. Please consult a SEBI-registered investment adviser and verify all data from official exchange filings before making any investment decision.
When is the Medicamen Biotech Q2 results date for FY27?
Ans. No official Medicamen Biotech Q2 results date has been announced yet for the quarter ended September 30, 2026.
What were Medicamen Biotech Ltd’s Q1 FY27 (Jun26) results?
Ans. In Q1 FY27, the company reported revenue of Rs 47.9 crore, operating profit of Rs 4.33 crore, an operating margin of 9.04%, and net profit of Rs 1.85 crore.
What was the Q2 FY26 (Sep25) base quarter performance?
Ans. In Sep25, revenue was Rs 47.17 crore, operating profit was Rs 5.16 crore, operating margin was 10.94%, and net profit was Rs 2.12 crore.
Was the Mar26 spike at Medicamen Biotech Ltd a one-off?
Ans. Yes, the company’s own data indicates the Mar26 sales and net profit spike to Rs 60.65 crore revenue and Rs 4.45 crore profit normalized in Jun26, likely a seasonal one-off.
